Related Experiment Video
Updated: Dec 25, 2025

Detecting the Ligand-binding Domain Dimerization Activity of Estrogen Receptor Alpha Using the Mammalian Two-Hybrid Assay
Published on: December 19, 2018
Modulation of androgen receptor DNA binding activity through direct interaction with the ETS transcription factor ERG
Elizabeth V Wasmuth1, Elizabeth A Hoover1, Albert Antar2
1Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065.
Abstract:
The androgen receptor (AR) is a type I nuclear hormone receptor and the primary drug target in prostate cancer due to its role as a lineage survival factor in prostate luminal epithelium. In prostate cancer, the AR cistrome is reprogrammed relative to normal prostate epithelium and particularly in cancers driven by oncogenic ETS fusion genes. The molecular basis for this change has remained elusive. Using purified proteins, we report a minimal cell-free system that demonstrates interdomain cooperativity between the ligand (LBD) and DNA binding domains (DBD) of AR, and its autoinhibition by the N terminus of AR. Furthermore, we identify ERG as a cofactor that activates AR's ability to bind DNA in both high and lower affinity contexts through direct interaction within a newly identified AR-interacting motif (AIM) in the ETS domain, independent of ERG's own DNA binding ability. Finally, we present evidence that this interaction is conserved among ETS factors whose expression is altered in prostate cancer. Our work highlights, at a biochemical level, how tumor-initiating ETS translocations result in reprogramming of the AR cistrome.
Insights
Androgen receptor (AR) reprogramming in prostate cancer involves ERG cofactor interaction. This biochemical insight explains how ETS fusions alter AR DNA binding, impacting cancer progression.
Area of Science:
- Molecular biology
- Cancer research
- Biochemistry
Background:
- The androgen receptor (AR) is a key target in prostate cancer.
- AR's role in prostate luminal epithelium survival is crucial.
- AR cistrome reprogramming occurs in prostate cancer, especially with ETS fusions, but the mechanism is unclear.
Purpose of the Study:
- To elucidate the molecular basis of AR cistrome reprogramming in prostate cancer.
- To investigate the role of ERG as a cofactor in AR DNA binding.
- To understand the biochemical interactions driving AR dysregulation in ETS-driven prostate cancers.
Main Methods:
- Utilized a minimal cell-free system with purified proteins.
- Investigated interdomain cooperativity within the AR.
- Identified and characterized the AR-interacting motif (AIM) in the ERG ETS domain.
Main Results:
- Demonstrated AR interdomain cooperativity and N-terminal autoinhibition.
- Identified ERG as an AR cofactor that enhances DNA binding.
- ERG interacts with AR via a novel AIM in the ETS domain, independent of ERG's DNA binding.
- This interaction is conserved across ETS factors implicated in prostate cancer.
Conclusions:
- Biochemical insights into AR-mediated transcriptional regulation in prostate cancer.
- ERG acts as a critical cofactor, reprogramming the AR cistrome.
- Understanding this interaction mechanism is vital for targeted prostate cancer therapies.
More Related Videos
06:21An Ecdysone Receptor-based Singular Gene Switch for Deliberate Expression of Transgene with Robustness, Reversibility, and Negligible Leakiness
Published on: May 7, 2018
09:07Prediction and Validation of Gene Regulatory Elements Activated During Retinoic Acid Induced Embryonic Stem Cell Differentiation
Published on: June 21, 2016
Related Concept Videos
RNA Polymerase II Accessory Proteins
Co-activators and Co-repressors
Master Transcription Regulators
Transducer Mechanism: Nuclear Receptors
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Eukaryotic Transcription Activators
The binding domains are capable of recognizing and interacting with regulatory sequences on the DNA. These...